Recalls
Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.
Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.
The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.
Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.
Minimum severity
Professional Compounding Pharmacy is recalling a compounded injectable drug because FDA inspectors observed insanitary conditions during its compounding.
Professional Compounding Pharmacy is recalling Acetyl-L-Cysteine 10% eye drops because FDA inspectors observed insanitary conditions during the compounding of sterile drugs.
McDaniel Life-Line LLC is voluntarily recalling 150 vials of Indian Herb Paste because the product is an unapproved new drug. The recall covers distribution in the US, Italy, Australia, Canada, and Poland.
Aurobindo Pharma USA Inc. is recalling 88,600 vials of MARBETA L KIT because one vial was found to contain a hair.
Professional Compounding Pharmacy is recalling Papaverine-Phentolamine 15-0.5mg/mL injectable vials because FDA inspectors observed insanitary conditions during the compounding of sterile drugs.
Professional Compounding Pharmacy is recalling PGE1 40 mcg/ml injectable vials because FDA inspectors observed insanitary conditions during the compounding of sterile drugs.
Professional Compounding Pharmacy is recalling specific lots of compounded Papaverine-Phentolamine-PGE1 injectable because FDA inspectors observed insanitary conditions during the compounding process.
Pfizer is recalling 8.4% Sodium Bicarbonate Injection vials because they contain glass particulates. The recall covers 283,400 vials distributed in the United States and Puerto Rico.
Legacy Pharmaceutical Packaging LLC is recalling Losartan Potassium Tablets, 50 mg, because an impurity was detected. The recall covers 179,544 bottles distributed in Arizona, Indiana, and Tennessee.
Ata International Inc is recalling Blue Fusion Capsules because FDA analysis found undeclared prescription ingredients, including Sildenafil and Tadalafil.
Advanced Pharma Inc. is recalling 22,900 syringes of Phenylephrine HCl injectable solution nationwide due to a lack of assurance of sterility.
Mylan Institutional, Inc. is recalling specific lots of Alprazolam Tablets, 0.25 mg, because elevated levels of a known impurity were detected during stability testing.
Aurobindo Pharma USA Inc. is recalling specific lots of Valsartan 40 mg tablets because FDA analysis found trace amounts of the impurity N-nitrosodiethylamine (NDEA).
Legacy Pharmaceutical Packaging LLC is recalling Losartan Potassium Tablets, 100 mg, due to the presence of the impurity N-Methylnitrosobutyric acid (NMBA).
Advanced Pharma Inc. is recalling 1,540 syringes of 2% Lidocaine HCl Injectable Solution because the company cannot assure the product's sterility.
Aurobindo Pharma USA is recalling specific lots of Valsartan 80 mg tablets because FDA analysis confirmed trace amounts of the impurity N-nitrosodiethylamine (NDEA).
Camber Pharmaceuticals is recalling Losartan Potassium tablets because trace amounts of the nitrosamine NMBA were detected in the active ingredient.
AvKARE Inc. is recalling Losartan Potassium and Hydrochlorothiazide Tablets because an impurity, N-Methylnitrosobutyric acid (NMBA), was identified.
Advanced Pharma Inc. is recalling 2,400 syringes of Hydromorphone HCl injectable solution nationwide due to a lack of assurance of sterility.
Advanced Pharma Inc. is recalling 5,700 syringes of Neostigmine Methylsulfate Injection Solution because there is a lack of assurance of sterility.
Advanced Pharma Inc. is recalling 1,125 bags of Midazolam Injectable Solution nationwide due to a lack of assurance of sterility.
Rising Pharmaceuticals is recalling Valsartan Tablets 320 mg due to CGMP deviations and the detection of a trace amount of the impurity N-nitrosodiethylamine (NDEA).
Rising Pharmaceuticals is recalling Valsartan Tablets 40 mg due to CGMP deviations and the detection of a trace amount of the impurity NDEA.
Legacy Pharmaceutical Packaging LLC is recalling Losartan Potassium Tablets, 25 mg, because an impurity was detected. The recall involves 456,732 bottles distributed by Wal-Mart.
Advanced Pharma Inc. is recalling 500 syringes of Heparin 10 Units/10 mL due to a lack of assurance of sterility. The product was distributed nationwide.